

Allergic Rhinitis (Respiratory) - Drugs In Development, 2021

<https://marketpublishers.com/r/A4B847904297EN.html>

Date: July 2021

Pages: 218

Price: US\$ 2,000.00 (Single User License)

ID: A4B847904297EN

Abstracts

Allergic Rhinitis (Respiratory) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Rhinitis - Drugs In Development, 2021, provides an overview of the Allergic Rhinitis (Respiratory) pipeline landscape.

Allergic rhinitis is an allergic reaction that happens when immune system overreacts to substances that is inhaled. An allergen is something that triggers an allergy. When a person with allergic rhinitis breathes in an allergen such as pollen, mold, animal dander, or dust, the body releases chemicals that cause allergy symptoms. Symptoms of allergic rhinitis include stuffy runny nose, sneezing, swollen eyelids, itchy mouth, throat, ears.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Rhinitis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Allergic Rhinitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Rhinitis (Respiratory) pipeline guide also reviews of key players involved in

therapeutic development for Allergic Rhinitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 1, 11, 12, 16, 1, 9 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 5 and 4 molecules, respectively.

Allergic Rhinitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Rhinitis (Respiratory).

The pipeline guide reviews pipeline therapeutics for Allergic Rhinitis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Allergic Rhinitis (Respiratory) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Allergic Rhinitis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Rhinitis (Respiratory)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Allergic Rhinitis (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Allergic Rhinitis (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Allergic Rhinitis - Overview

Allergic Rhinitis - Therapeutics Development

Allergic Rhinitis - Therapeutics Assessment

Allergic Rhinitis - Companies Involved in Therapeutics Development

Allergic Rhinitis - Drug Profiles

Allergic Rhinitis - Dormant Projects

Allergic Rhinitis - Discontinued Products

Allergic Rhinitis - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Allergic Rhinitis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Companies, 2021 (Contd..2)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Target, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Allergic Rhinitis - Pipeline by Advagene Biopharma Co Ltd, 2021
Allergic Rhinitis - Pipeline by ALK-Abello AS, 2021
Allergic Rhinitis - Pipeline by Allovate LLC, 2021
Allergic Rhinitis - Pipeline by AOBiome LLC, 2021
Allergic Rhinitis - Pipeline by ASIT Biotech SA, 2021
Allergic Rhinitis - Pipeline by Astellas Pharma Inc, 2021
Allergic Rhinitis - Pipeline by Bai Shuo Beijing Pharmaceutical Technology Co Ltd, 2021
Allergic Rhinitis - Pipeline by Cadila Healthcare Ltd, 2021
Allergic Rhinitis - Pipeline by Chrysalis BioTherapeutics Inc, 2021
Allergic Rhinitis - Pipeline by CSPC Pharmaceutical Group Ltd, 2021
Allergic Rhinitis - Pipeline by Dobecure SL, 2021
Allergic Rhinitis - Pipeline by DongKoo Bio & Pharma Co Ltd, 2021
Allergic Rhinitis - Pipeline by Emergo Therapeutics Inc, 2021
Allergic Rhinitis - Pipeline by FunPep Co Ltd, 2021
Allergic Rhinitis - Pipeline by GL Pharm Tech Corp, 2021
Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd, 2021
Allergic Rhinitis - Pipeline by HAL Allergy BV, 2021
Allergic Rhinitis - Pipeline by Inimmune Corp, 2021
Allergic Rhinitis - Pipeline by Inmunotek SL, 2021

Allergic Rhinitis - Pipeline by Kolmar Pharma Co Ltd, 2021
Allergic Rhinitis - Pipeline by Liminal BioSciences Inc, 2021
Allergic Rhinitis - Pipeline by Link Health Group, 2021
Allergic Rhinitis - Pipeline by Marinomed Biotech AG, 2021
Allergic Rhinitis - Pipeline by MD Healthcare Inc, 2021
Allergic Rhinitis - Pipeline by Mitsubishi Tanabe Pharma Corp, 2021
Allergic Rhinitis - Pipeline by Nasus Pharma Ltd, 2021
Allergic Rhinitis - Pipeline by Navipharm Co Ltd, 2021
Allergic Rhinitis - Pipeline by Novartis AG, 2021
Allergic Rhinitis - Pipeline by Oneness Biotech Co Ltd, 2021
Allergic Rhinitis - Pipeline by Paradigm Biopharmaceuticals Ltd, 2021
Allergic Rhinitis - Pipeline by PharmaKing Co Ltd, 2021
Allergic Rhinitis - Pipeline by Regeneron Pharmaceuticals Inc, 2021
Allergic Rhinitis - Pipeline by Roxall Medizin GmbH, 2021
Allergic Rhinitis - Pipeline by Sama Pharm Co Ltd, 2021
Allergic Rhinitis - Pipeline by Sedor Pharmaceuticals LLC, 2021
Allergic Rhinitis - Pipeline by Shouyao Holding Co Ltd, 2021
Allergic Rhinitis - Pipeline by Siolta Therapeutics Inc, 2021
Allergic Rhinitis - Pipeline by Stallergenes Greer Ltd, 2021
Allergic Rhinitis - Pipeline by Synokem Pharmaceuticals Ltd, 2021
Allergic Rhinitis - Pipeline by The Geneva Biotech Center SA, 2021
Allergic Rhinitis - Pipeline by United Biomedical Inc, 2021
Allergic Rhinitis - Pipeline by Vactech Oy, 2021
Allergic Rhinitis - Pipeline by Wolwo Pharma, 2021
Allergic Rhinitis - Pipeline by Wuhan Yicheng Biotechnology Co Ltd, 2021
Allergic Rhinitis - Dormant Projects, 2021
Allergic Rhinitis - Dormant Projects, 2021 (Contd..1)
Allergic Rhinitis - Dormant Projects, 2021 (Contd..2)
Allergic Rhinitis - Dormant Projects, 2021 (Contd..3)
Allergic Rhinitis - Dormant Projects, 2021 (Contd..4)
Allergic Rhinitis - Dormant Projects, 2021 (Contd..5)
Allergic Rhinitis - Dormant Projects, 2021 (Contd..6)
Allergic Rhinitis - Dormant Projects, 2021 (Contd..7)
Allergic Rhinitis - Discontinued Products, 2021
Allergic Rhinitis - Discontinued Products, 2021 (Contd..1)

List Of Figures

LIST OF FIGURES

- Number of Products under Development for Allergic Rhinitis, 2021
- Number of Products under Development by Companies, 2021
- Number of Products under Development by Universities/Institutes, 2021
- Number of Products by Top 10 Targets, 2021
- Number of Products by Stage and Top 10 Targets, 2021
- Number of Products by Top 10 Mechanism of Actions, 2021
- Number of Products by Stage and Top 10 Mechanism of Actions, 2021
- Number of Products by Top 10 Routes of Administration, 2021
- Number of Products by Stage and Top 10 Routes of Administration, 2021
- Number of Products by Top 10 Molecule Types, 2021
- Number of Products by Stage and Top 10 Molecule Types, 2021

I would like to order

Product name: Allergic Rhinitis (Respiratory) - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/A4B847904297EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A4B847904297EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970